277 related articles for article (PubMed ID: 34001187)
21. Tolerance and toxicity of primary radiation therapy in the management of seropositive HIV patients with squamous cell carcinoma of the head and neck.
Mourad WF; Hu KS; Ishihara D; Shourbaji RA; Lin W; Kumar M; Jacobson AS; Tran T; Manolidis S; Urken M; Persky M; Harrison L
Laryngoscope; 2013 May; 123(5):1178-83. PubMed ID: 23532683
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy.
Lee TF; Fang FM
Radiother Oncol; 2013 Mar; 106(3):352-8. PubMed ID: 23333019
[TBL] [Abstract][Full Text] [Related]
23. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
24. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
25. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
PLoS One; 2018; 13(7):e0200137. PubMed ID: 29979726
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic alterations and their molecular genetic correlates in head and neck squamous cell carcinoma: a next generation window to the biology of disease.
Gollin SM
Genes Chromosomes Cancer; 2014 Dec; 53(12):972-90. PubMed ID: 25183546
[TBL] [Abstract][Full Text] [Related]
27. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
Tillman BN; Yanik M; Birkeland AC; Liu CJ; Hovelson DH; Cani AK; Palanisamy N; Carskadon S; Carey TE; Bradford CR; Tomlins SA; McHugh JB; Spector ME; Brenner JCh
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1646-52. PubMed ID: 26849095
[TBL] [Abstract][Full Text] [Related]
29. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.
Solis RN; Silverman DA; Birkeland AC
Curr Treat Options Oncol; 2022 Feb; 23(2):254-267. PubMed ID: 35195839
[TBL] [Abstract][Full Text] [Related]
30. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy.
Mourad WF; Hu KS; Shasha D; Concert C; Ishihara D; Lin W; Gamez ME; Lukens JN; Shourbaji RA; Ryniak M; Li Z; Culliney BE; Khorsandi AS; Tran T; Jacobson A; Manolidis S; Schantz S; Urken M; Persky MS; Harrison LB
Anticancer Res; 2013 Dec; 33(12):5511-6. PubMed ID: 24324090
[TBL] [Abstract][Full Text] [Related]
32. Radiation-induced hypothyroidism after treatment of head and neck cancer.
Feen Rønjom M
Dan Med J; 2016 Mar; 63(3):. PubMed ID: 26931197
[TBL] [Abstract][Full Text] [Related]
33. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires.
Holländer-Mieritz C; Johansen J; Johansen C; Vogelius IR; Kristensen CA; Pappot H
Acta Oncol; 2019 May; 58(5):603-609. PubMed ID: 30698098
[No Abstract] [Full Text] [Related]
34. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
[TBL] [Abstract][Full Text] [Related]
35. Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
Borchiellini D; Etienne-Grimaldi MC; Bensadoun RJ; Benezery K; Dassonville O; Poissonnet G; Llorca L; Ebran N; Formento P; Château Y; Thariat J; Milano G
Oral Oncol; 2017 Apr; 67():70-76. PubMed ID: 28351583
[TBL] [Abstract][Full Text] [Related]
36. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
[TBL] [Abstract][Full Text] [Related]
37. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance.
Hess J; Unger K; Orth M; Schötz U; Schüttrumpf L; Zangen V; Gimenez-Aznar I; Michna A; Schneider L; Stamp R; Selmansberger M; Braselmann H; Hieber L; Drexler GA; Kuger S; Klein D; Jendrossek V; Friedl AA; Belka C; Zitzelsberger H; Lauber K
Cancer Lett; 2017 Feb; 386():87-99. PubMed ID: 27867017
[TBL] [Abstract][Full Text] [Related]
38. What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria.
Merlotti A; Mazzola R; Alterio D; Alongi F; Bacigalupo A; Bonomo P; Maddalo M; Russi EG; Orlandi E
Crit Rev Oncol Hematol; 2017 Mar; 111():20-30. PubMed ID: 28259292
[TBL] [Abstract][Full Text] [Related]
39. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
40. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
